Ultimately, clinical trials such as these have confirmed that, similar to sodium/glucose cotransporters 2 (SGLT2) inhibitors, GLP‐1 mimetics have established cardiovascular disease benefits in diabetes. Here, GLP1R is linked to diabetes mellitus.